Reduction in number of falls

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

The vaginal bowel control system achieved a 72.6% success rate (50% or greater reduction in FI episodes) at 3 months in the ITT population, with success rates sustained at 6 and 12 months and reaching

Effect: improvement; 72.6% success rate (ITT) at 3 months; CI: 95% CI, 61%-82%

OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day

Effect: null; 3.3 vs 3.4 episodes per day reduction

OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day

Effect: null; 3.3 vs 3.4 episodes per day reduction

OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day

Effect: null; 3.3 vs 3.4 episodes per day reduction

OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day

Effect: null; 3.3 vs 3.4 episodes per day reduction

OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day

Effect: null; 3.3 vs 3.4 episodes per day reduction

OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day

Effect: null; 3.3 vs 3.4 episodes per day reduction

OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day

Effect: null; 3.3 vs 3.4 episodes per day reduction

OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day

Effect: null; 3.3 vs 3.4 episodes per day reduction

OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day

Effect: null; 3.3 vs 3.4 episodes per day reduction

OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day

Effect: null; 3.3 vs 3.4 episodes per day reduction

OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day

Effect: null; 3.3 vs 3.4 episodes per day reduction

OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day

Effect: null; 3.3 vs 3.4 episodes per day reduction

OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day

Effect: null; 3.3 vs 3.4 episodes per day reduction

OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day

Effect: null; 3.3 vs 3.4 episodes per day reduction

OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day

Effect: null; 3.3 vs 3.4 episodes per day reduction

OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day

Effect: null; 3.3 vs 3.4 episodes per day reduction

OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day

Effect: null; 3.3 vs 3.4 episodes per day reduction

OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day

Effect: null; 3.3 vs 3.4 episodes per day reduction

OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day

Effect: null; 3.3 vs 3.4 episodes per day reduction

OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day

Effect: null; 3.3 vs 3.4 episodes per day reduction

OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day

Effect: null; 3.3 vs 3.4 episodes per day reduction

OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day

Effect: null; 3.3 vs 3.4 episodes per day reduction

OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day

Effect: null; 3.3 vs 3.4 episodes per day reduction